Stifel reiterates Plexus stock rating after investor site visit By Investing.com

Stifel reiterated a Buy rating and $280 price target on Plexus Corp., implying about 5% upside from the current $265.72 share price and reinforcing its view that the company is at an inflection point. The firm also highlighted strong momentum after the stock’s 105% gain over the past year and recent earnings that beat estimates, with Q2 FY2026 EPS of $2.05 versus $1.88 consensus and revenue of $1.164B versus $1.13B expected. Shares still trade near their 52-week high of $275.83, though InvestingPro noted the stock appears overvalued relative to fair value.

Analysis

The important signal here is not the valuation call itself but the combination of a recent operating beat, management access, and a reaffirmed upgrade cycle. That tends to extend multiple support for a name that is already near highs, because incremental buyers are often forced to chase into strength when both the sell side and the company are reinforcing the same narrative. The medium-term setup is less about a single quarter and more about whether this becomes a sustained margin-reexpansion story, which can keep the stock elevated even if top-line growth normalizes.

The second-order winner may be other high-mix, engineering-intensive EMS providers and niche hardware suppliers tied to defense/aerospace and industrial programs. If Plexus is indeed entering an inflection point, it suggests customers are prioritizing execution, localization, and design-for-manufacturability over pure labor cost arbitrage, which is a favorable backdrop for firms with sticky design wins and less favorable for commoditized contract manufacturers. The broader implication is that quality EMS platforms can command a premium when end markets are fragmented and OEMs want resilience over cheapest-cost sourcing.

The main risk is timing: after a sharp run, the market may already be discounting most of the near-term upside, so the next catalyst likely needs to be either another upward guide or evidence of margin flow-through over the next 1-2 quarters. If growth merely meets expectations, the stock can de-rate quickly from an elevated multiple, especially if investors rotate into lower-beta industrials. The contrarian read is that the ‘inflection’ may be more mature than the market assumes, meaning the easy money has been made and the next 10-15% upside depends on sustained estimate revisions rather than headline enthusiasm.

Key Decisions for Investors

• Stay long PLXS but use call spreads, not outright stock, for the next 1-2 quarters: buy 6-9 month $260/$300 call spreads to capture continued estimate revisions with defined premium at risk.
• For investors already long PLXS, trim 20-30% into strength above prior highs and re-add on any post-earnings gap down that remains above the 50-day moving average; this is a momentum stock, but crowded longs can unwind fast.
• Pair trade idea: long PLXS / short a lower-quality EMS peer or industrial hardware assembler with weaker margin visibility over the next 3-6 months; the relative setup favors names with genuine operating inflection over names with only cyclical beta.
• If PLXS closes below the 50-day average after the next earnings update, cut the trade aggressively: the risk/reward flips quickly because the stock’s current setup is valuation-sensitive and momentum-dependent.
• For event-driven accounts, consider selling put spreads 10-15% below spot into the next earnings cycle; if the thesis is correct, implied volatility should remain well-supported, but the downside should be buffered by current operating momentum.